Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus.

Yuntao ZhangHaiping ChenJun LvTao HuangRuizhi ZhangDongjuan ZhangLinyun LuoSheng WeiXiaoqin LiuShangxiao ZhangQiuyue MuRongdong HuangJiao HuangYanhui XiaoYunkai YangYuting HanHao GongQinghu GuanFangqin XieHui WangLiming LiXiaoming Yang

Published in: Vaccines (2022)

The COVID-19 vaccine (Vero cell), inactivated, showed good immunogenicity and safety in patients aged ≥60 years suffering from hypertension or(/and) diabetes mellitus.

Keyphrases

coronavirus disease
sars cov
blood pressure
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
physical activity
prognostic factors
stem cells
skeletal muscle
respiratory syndrome coronavirus
community dwelling
adipose tissue
mesenchymal stem cells
arterial hypertension